

ESMO PRECEPTORSHIP PROGRAMME ADOLESCENTS & YOUNG ADULTS MALIGNANCIES

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Lugano, Switzerland
11-12 May 2018

CO-CHAIRS:

Giannis Mountzios, Greece
Stefan Bielack, Germany

SPEAKERS:

Nicolas Boissel, France
Laurence Brugières, France
Jean-Yves Douillard, Switzerland
Didier Frappaz, France
Suzanne Kaal, Netherlands
Fedro Peccatori, Italy
Emmanouil Saloustros, Greece
Daniel Stark, United Kingdom

LEARNING OBJECTIVES

- To identify the unique characteristics and the unmet needs of adolescents and young adults (AYA) with cancer
- To describe the unique constellation of malignancies that comprise the spectrum of AYA cancer
- To analyse epidemiology, biology, clinical features and diagnostic challenges of AYA with cancer
- To emphasize on radicality of treatment, multidisciplinary and psychosocial support of AYA
- To discuss survivorship issues including late sequelae of treatment and the urgent need for clinical trials

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Luigi Taddei 4
6962 Lugano – Viganello
Switzerland
Email: courses@esmo.org
www.esmo.org

Friday, 11 May 2018

09:00-09:15 15'	Opening and Welcome	
5'	Welcome on behalf of ESMO	Giannis Mountzios, GR
5'	Welcome on behalf of SIOPE	Stefan Bielack, DE
5'	Education at ESMO	Jean-Yves Douillard, CH
09:15-10:05 50'	Session 1 Definition and epidemiology of AYA cancer	Chair: Daniel Stark, UK
20'	The unique constellation of tumours in AYA: not a child, not an adult	Giannis Mountzios, GR
30'	Epidemiology of AYA tumours	Daniel Stark, UK
10:05-10:30	Coffee break	
10:30-11:40 70'	Session 2 Genetics, clinical features and diagnosis	Chair: Fedro Peccatori, IT
20'	Main genetic alterations in AYA with cancer	Emmanouil Saloustros, GR
30'	The pathway of care: who refers the patient to whom	Daniel Stark, UK
20'	Clinical presentation of tumours and diagnostic challenges	Fedro Peccatori, IT
11:40-12:40 60'	Session 3 Leukaemias and Lymphomas	Chair: Laurence Brugières, FR
30'	Leukaemias	Nicolas Boissel, FR
30'	Lymphomas	Laurence Brugières, FR
12:40-13:40	Lunch	
13:40-14:40 60'	Session 4 Sarcomas	Chair: Fedro Peccatori, IT
30'	Bone sarcomas	Stefan Bielack, DE
30'	Soft tissue sarcomas	Stefan Bielack, DE
14:40-15:40 60'	Session 5 Brain and germ-cell tumours	Chair: Stefan Bielack, DE
30'	Brain tumours	Didier Frappaz, FR
30'	Germ-cell tumours	Giannis Mountzios, GR
15:40-16:10	Coffee break	
16:10-17:55 105'	Session 6 „Adult type“ tumours in AYA	Chair: Giannis Mountzios, GR
20'	Colorectal cancer in AYA: focus on hereditary colorectal cancer syndromes	Emmanouil Saloustros, GR
20'	Breast cancer in girls and young women	Fedro Peccatori, IT
20'	Juvenile melanoma	Emmanouil Saloustros, GR
3x15'	3 x Participant clinical case discussion	Faculty
19:30	Dinner	

Saturday, 12 May 2018

09:00-10:20 80'	Session 7 Treatment and sequelae of treatment	Chair: Giannis Mountzios, GR
20'	General principles of treatment in AYA with cancer	Daniel Stark, UK
30'	Late effects of treatment	Laurence Brugières, FR
30'	Effects of chemotherapy and radiotherapy	Giannis Mountzios, GR
10:20-10:50	Coffee break	
10:50-12:10 80'	Session 8 Special Issues	Chair: Giannis Mountzios, GR
30'	Fertility preservation	Fedro Peccatori, IT
30'	Cancer and pregnancy	Fedro Peccatori, IT
20'	Access to clinical trials, International initiatives	Stefan Bielack, DE
12:10-14:05 115'	Session 9 Cancer Survivorship	Chair: Fedro Peccatori, IT
30'	Lifestyle interventions	Suzanne Kaal, NL
30'	Psychological support: focus on professional and social reintegration	Suzanne Kaal, NL
3x15'	3 x Participant clinical case discussion	Faculty
10'	Wrap-up and farewell	Giannis Mountzios, GR Stefan Bielack, DE
14:05-14:45	Lunch	

Note: Each 15 minutes slot for clinical case discussion includes 5' case presentation and 10 Q&A/panel discussion